Swedish Orphan Biovitrum

Swedish Orphan Biovitrum (Sobi) is a leading biotech business focusing on rare diseases, a global presence, and scientific innovation, making it a key player in the healthcare market.

Sobi focuses on researching and developing medicines for rare diseases, with a particular emphasis on hemophilia, inflammation, and genetic and metabolic problems. They are committed to making a difference in the lives of patients suffering from these disorders, which frequently have few therapeutic alternatives.

Sobi has offices throughout Europe, North America, and the Middle East. They work with healthcare providers, patient organizations, and other stakeholders worldwide to further their purpose of enhancing patients' lives.

Sobi's R&D efforts are focused on finding novel medicines for rare diseases by using cutting-edge technology and scientific methodologies. The company has a proven track record of developing innovative products, including numerous authorized therapies for uncommon disorders.

Sobi is committed to sustainability and social responsibility and has implemented many efforts to reduce its environmental footprint while supporting community development and education. In keeping with their firm beliefs, they try to create a beneficial influence beyond healthcare.

Founded: 2001

Headquarters: Stockholm, Sweden

Website: https://www.sobi.com/